Increased C-Reactive Protein Levels in the Polycystic Ovary Syndrome: A Marker of Cardiovascular Disease

Journal of Clinical Endocrinology and Metabolism

Volumn 89, Issue 5, 2004, Pages 2160-2165

  Boulman, N ^a   Levy, Y ^a   Leiba, R ^a,b   Shachar, S ^b   Linn, R ^a,b   Zinder, O ^a   Blumenfeld, Z ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; GLUCOSE; HOMOCYSTEINE; THYROTROPIN;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; GLUCOSE BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; METABOLIC REGULATION; ONSET AGE; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; REPRODUCTION; RISK FACTOR; STATISTICAL SIGNIFICANCE; STROKE; THYROTROPIN BLOOD LEVEL;

ADULT; BIOLOGICAL MARKERS; BODY MASS INDEX; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; OSMOLAR CONCENTRATION; POLYCYSTIC OVARY SYNDROME; RETROSPECTIVE STUDIES;

FALLOPIA;

EID: 2442434415     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-031096     Document Type: Article

References (34)

1. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R 1998 Prevalence of the polycystic ovary syndrome in unselected black and white women of southeastern United States: a prospective study. J Clin Endocrinol Metab 83:3078-3082
2. Franks S 1995 Polycystic ovary syndrome. N Engl J Med 333:853-861
3. Zawadzki JK, Dunaif A 1992 Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Hasetline FP, Merriam GR, eds. Current issues in endocrinology and metabolism, vol 4, chapt 32. Boston: Blackwell; 377 (Clinical manifestation of polycystic ovary syndrome in adult, www.uptodate.com)
4. Conway GS, Agrawal R, Betteridge DJ, Jacobs HS 1992 Risk factors for coronary artery disease in lean and obese women with the PCOS. Clin Endocrinol (Oxf) 37:119-125
5. Talbott EO, Zborowski JV, Sutton-Tyrrell K, McHugh-Pemu KP, Guzick DS 2001 Cardiovascular risk in women with polycystic ovary syndrome. Obstet Gynecol Clin North Am 28:111-133
6. Talbott E, Guzick D, Clerici A, Berga S, Detre K, Weimer K, Kuller L 1995 Coronary heart disease risk factor in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol 15:821-826
7. Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB 1985 Lipoprotein lipid concentration and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab 61:946-951
8. Glueck CJ, Papanna P, Wang P, Gildenberg N, Sieve-Smith L 2003 Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism 52:908-915
9. Talbott EO, Guzick DS, Sutton-Tyrrell K, McHugh-Pemu KP, Zborowski JV, Remsberg KE, Kuller LH 2000 Evidence for as association between polycystic ovary and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 20:2414-2421
10. Christian RC, Dumesic DA, Behrenbeck T, Oberg AL, Sheedy II PF, Fitzpatrick LA 2003 Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88:2562-2568
11. Wild S, Pierpoint T, McKeigue P, Jacobs H 2000 Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 52:595-600
12. Morin-Papunen L, Rautio K, Ruokonen A, Hedberg P, Puukka M, Tapanainen JS 2000 Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study. Hum Fertil 3:101-105
13. Ridker PM 2003 Clinical application of C-reactive protein for cardiovascular disease: detection and prevention. Circulation 107:363-369
14. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR 2002 Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular event. N Engl J Med 347:1557-1565
15. Ridker PM, Hennekens CH, Buring JE, Rifai N 2000 C-reactive protein and other markers of inflammation in the predictor of cardiovascular disease in women. N Engl J Med 342:836-843
16. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon III RO, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith Jr SC, Taubert K, Tracy RP, Vinicor F, Centers of Disease Control and Prevention, American Heart Association 2003 Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Center for Disease Control and Prevention and the American Heart Association. Circulation 107:499-511
17. Ridker PM, Buring JE, Cook NR, Rifai N 2003 C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14719 initially healthy American women. Circulation 107:391-397
18. Kelly C, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N 2001 Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 86:2453-2455
19. Fenkci V, Fenkci S, Yilmazer M, Serteser M 2003 Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertil Steril 80: 123-127
20. Passing H, Bablok W 1983 A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, part I. J Clin Chem Clin Biochem 21:709-720
21. Whicher JT, Ritchie RF, Johnson AM, Baudner S, Bienvenu J, Blirup-Jensen S, Carlstorm A, Dati F, Ward AM, Svendsen PJ 1994 New international reference preparation for proteins in human serum (RPPHS). Clin Chem 40: 934-938
22. Dati F, Schumann G, Thomas L, Aguzzi F, Baudner S, Bienvenu J, Blaabjerg O, Blirup-Jensen S, Carlstrom A, Petersen PH, Johnson AM, Milford-Ward A, Ritchie RF, Svendsen PJ, Whicher J 1996 Consensus of a group professional societies and diagnostic companies guidelines for interim reference ranges for 14 proteins in serum based on standardization against the IFCC/BCR/CAP Reference Material (CRM 4 International Federation of Clinical Chemistry. Community Bureau of Reference of the Commission of the European Communities. College of American Pathologists. Eur J Clin Chem Clin Biochem 34:517-520
23. Wild RA 2002 Polycystic ovary syndrome: a risk for coronary artery disease? Am J Obstet Gynecol 186:35-43
24. Harborne L, Fleming R, Lyall H, Norman J, Sattar N 2003 Descriptive review of the evidence for use of metformin in polycystic ovary syndrome. Lancet 361:1894-1901
25. Guzick DS, Talbott EO, Sutton-Tyrrell K, Herzog HC, Kuller LH, Wolfson Jr SK 1996 Carotid atherosclerosis in women with polycystic ovary syndrome: initial result from a case-control study. Am J Obstet Gynecol 174:1224-1229
26. Dahlgren E, Janson PO, Johansson S, Lapidus L, Oden A 1992 Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand 71:599-604
27. Birdsall MA, Farquhar CM, White HD 1997 Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Ann Intern Med 126:32-35
28. Solomon CG, Hu FB, Dunaif A, Rich-Edwards JE, Stampfer MJ, Willett WC, Speizer FE, Manson JE 2002 Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab 87:2013-2017
29. Legro RS 2003 Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev 24:302-312
30. Ford ES, Wayne HG, Dietz II W 2002 Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 287:356-359
31. Stadtmauer LA, Wong BC, Oehninger S 2002 Should patients with polycystic ovary syndrome be treated with metformin? Benefits of insulin sensitizing drugs in polycystic ovary syndrome: beyond ovulation induction. Hum Reprod 17:3016-3026
32. Pirwani I, Fleming R, Greer IA, Packard CJ, Sattar N 2001 Lipids and lipoprotein subfractions in women with PCOS. Clin Endocrinol (Oxf) 54: 447-454
33. Gorgels WJ, Graaf Y, Blankenstein MA, Collette HJ, Erkelens DW, Banga JD 1997 Urinary sex hormone excretions in premenopausal women and coronary heart disease risk: a nested case-referent study in the DOM-cohort J Clin Epidemiol 50:275-281
34. Morin-Papunen L, Rautio K, Ruokonen A, Hedberg P, Puukka M, Tapanainen JS 2003 Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88:4649-4654